Filing Details
- Accession Number:
- 0001209191-24-002881
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-06 08:27:19
- Reporting Period:
- 2024-02-05
- Accepted Time:
- 2024-02-06 08:27:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1633932 | Essa Pharma Inc. | EPIX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1826322 | Peter Virsik | C/O Essa Pharma Inc. 999 West Broadway, Suite 720 Vancouver A1 V5Z 1K5 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Disposition | 2024-02-05 | 694 | $9.25 | 13,328 | No | 4 | S | Direct | |
| Common Shares | Acquisiton | 2024-02-05 | 500 | $3.23 | 13,828 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2024-02-05 | 500 | $10.04 | 13,328 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Options | Disposition | 2024-02-05 | 500 | $0.00 | 500 | $3.23 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 967,782 | 2023-10-07 | 2029-10-07 | No | 4 | M | Direct |
Footnotes
- Reflects a transaction effected pursuant to Mr. Virsik's 10b5-1 trading plan. The Rule 10b5-1 trading plan was entered into on August 31, 2023.
- The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
